Atlanta Allergy & Asthma is currently enrolling participants for the VITESSE Pediatric Peanut Allergy study. Atlanta Allergy & Asthma’s Research Department has been actively involved in conducting clinical research studies for more than 40 years. These studies help in the development of new therapies for patients with allergic diseases and asthma. You do not have to be a patient of Atlanta Allergy & Asthma to be considered for a clinical trial.
Learn more about the VITESSE study below.
What Is the VITESSE study?
The VITESSE Phase 3 pediatric peanut allergy study is evaluating an investigational drug patch called DBV712 for children 4 to 7 years of age with peanut allergy. The main purpose of this study is to learn how well the investigational drug (also called study drug) patch (DBV712) works and how safe it is compared with a placebo patch in children with peanut allergy. The small amount of peanut protein in the study drug patch is designed to potentially desensitize (or make less sensitive) a peanut-allergic person by repeated exposures to very small amounts of peanut.
Qualifications to be considered for this study:
- Children ages 4 to 7 who have been diagnosed with a peanut allergy (cannot be 8 on screening day)
- Currently following a strict, peanut-free diet
- Physician-diagnosed peanut allergy or children with a well-documented medical history of Ige-mediated reaction(s) after ingestion with peanut.
- Excludes: Current immunotherapy for any allergen (including environmental & insect allergy)
- Excludes: Monoclonal antibody therapy within 6 months of screening
- Excludes: Uncontrolled persistent asthma
How Long Will My Child Be in This Study?
You and your child will be asked to attend at least 12 study visits over a period of approximately 58 weeks (about 1 year). During this period, a study team member will also call you a minimum of 5 times in between visits to check on your child.